A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL

Inclusion Criteria:

- Histologically confirmed aggressive B-cell DLBCL, including FL transforming to DLBCL
& Grade III FL

- Relapsed from or refractory to at least one treatment containing rituximab or another
anti-CD20 based immunotherapy combined with anthracycline- or anthracenedione-based
chemotherapy

- Eligible for ASCT

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Life expectancy of ≥ 12 weeks

- Adequate hematological function

Exclusion Criteria:

- Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal
therapy for treatment of lymphoma within 28 days prior to treatment

- Previous cancer therapy for DLBCL other than anthracycline- or anthracenedione based
chemoimmunotherapy, monotherapy rituximab prior to first line therapy and/or as a
maintenance therapy, or limited field radiotherapy

- Prior autologous or allogeneic SCT

- New York Heart Association ≥ Class II congestive heart failure; Clinically
significant abnormality on ECG

- History of other invasive malignancy within 5 years except for localized/in situ,
carcinomas such as cervical carcinoma in situ.

- Evidence of active infection

- Documented current central nervous system involvement by leukemia or lymphoma